Godwin, Andrew K.
22 papers on CoChatORCID 0000-0002-3987-9580
Most cited papers
- Verified
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity
Cancer Immunotherapy and BiomarkersImmune cells in cancer
Cited by 5,870
- Verified
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGene expression and cancer classification
Cited by 3,725
- Verified
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 3,201
- Verified
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGene expression and cancer classification
Cited by 2,546
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGenomics and Rare Diseases
Cited by 2,256
- Verified
Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 1,125
- Verified
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 820
- Verified
Proteogenomic and metabolomic characterization of human glioblastoma
Wang, L.-B., Karpova, A., Gritsenko, M. A., Kyle, J. E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J. H., Hong, R., et al. (2021) · Cancer Cell
Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics
Cited by 661
- Verified
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell
PI3K/AKT/mTOR signaling in cancerCancer Genomics and Diagnostics
Cited by 626
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 552
- Verified
Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer
Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D. F., Antoniou, A. C., et al. (2015) · JAMA
BRCA gene mutations in cancerMultiple and Secondary Primary Cancers
Cited by 521
- Verified
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports
Hippo pathway signaling and YAP/TAZCancer-related molecular mechanisms research
Cited by 500
- Verified
Proteogenomic Characterization of Endometrial Carcinoma
Dou, Y., Kawaler, E. A., Cui Zhou, D., Gritsenko, M. A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V. A., Savage, S. R., Satpathy, S., et al. (2020) · Cell
Endometrial and Cervical Cancer TreatmentsAdvanced Proteomics Techniques and Applications
Cited by 485
- Verified
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems
Cancer Genomics and DiagnosticsCancer-related Molecular Pathways
Cited by 431
- Verified
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 399
- Verified
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.
Rebbeck, T. R., Kantoff, P. W., Krithivas, K., Neuhausen, S., Blackwood, M. A., Godwin, A. K., Daly, M. B., Narod, S. A., Garber, J. E., Lynch, H. T., et al. (1999) · The American Journal of Human Genetics
BRCA gene mutations in cancerGenetic factors in colorectal cancer
Cited by 252
- Verified
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
EMBRACE, Kuchenbaecker, K. B., Collaborators, G. S., Breast Cancer Family Registry, HEBON, KConFab Investigators, Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study Group, the Consortium of Investigators of Modifiers of BRCA1 and BRCA2, Ramus, S. J., et al. (2015) · Nature Genetics
BRCA gene mutations in cancerOvarian cancer diagnosis and treatment
Cited by 250
- Verified
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
EMBRACE, Dunning, A. M., Collaborators, G. S., HEBON, kConFab Investigators, Michailidou, K., Kuchenbaecker, K. B., Thompson, D., French, J. D., Beesley, J., et al. (2016) · Nature Genetics
Genetic Associations and EpidemiologyEstrogen and related hormone effects
Cited by 161
- Verified
Subtypes of familial breast tumours revealed by expression and copy number profiling
kConFab Investigators, Waddell, N., Arnold, J., Cocciardi, S., da Silva, L., Marsh, A., Riley, J., Johnstone, C. N., Orloff, M., Assie, G., et al. (2010) · Breast Cancer Research and Treatment
Breast Cancer Treatment StudiesBRCA gene mutations in cancer
Cited by 99
- Verified
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32, 295 women
EMBRACE, Rebbeck, T. R., HEBON, Friebel, T. M., Mitra, N., Wan, F., Chen, S., Andrulis, I. L., Apostolou, P., Arnold, N., et al. (2016) · Breast Cancer Research
BRCA gene mutations in cancerMultiple and Secondary Primary Cancers
Cited by 71
- Verified
Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation
Britt, A., Mohyuddin, G. R., McClune, B., Singh, A., Lin, T., Ganguly, S., Abhyankar, S., Shune, L., McGuirk, J., Skikne, B., et al. (2020) · Leukemia Research
Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation
Cited by 21
- Verified
Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).
Sharma, P., Kimler, B. F., O'Dea, A., Nye, L. E., Wang, Y. Y., Yoder, R., Prochaska, L. H., Wagner, J. L., Amin, A. L., Larson, K., et al. (2019) · Journal of Clinical Oncology
Breast Cancer Treatment StudiesCancer Treatment and Pharmacology
Cited by 13
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free